AR060471A1 - Organismos clostridium recombinantes atenuados y vacuna - Google Patents

Organismos clostridium recombinantes atenuados y vacuna

Info

Publication number
AR060471A1
AR060471A1 ARP070101608A ARP070101608A AR060471A1 AR 060471 A1 AR060471 A1 AR 060471A1 AR P070101608 A ARP070101608 A AR P070101608A AR P070101608 A ARP070101608 A AR P070101608A AR 060471 A1 AR060471 A1 AR 060471A1
Authority
AR
Argentina
Prior art keywords
organisms
recombinants
vaccine
damaged
attenuated
Prior art date
Application number
ARP070101608A
Other languages
English (en)
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of AR060471A1 publication Critical patent/AR060471A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Feed For Specific Animals (AREA)

Abstract

Organismos Clostridium perfringens atenuados, que expresan una toxina alfa sustancialmente no toxica. La toxina alfa expresada es una muteína de delecion a la que, en relacion con la toxina alfa de la toxina alfa madura de la cepa 13 de Clostridium perfringens, le faltan por lo menos 9 residuos de aminoácidos consecutivos, que incluyen His68. Además organismos atenuados que codifican las muteínas, y también, el uso de dichos organismos atenuados como vacunas.
ARP070101608A 2006-04-17 2007-04-16 Organismos clostridium recombinantes atenuados y vacuna AR060471A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79255306P 2006-04-17 2006-04-17

Publications (1)

Publication Number Publication Date
AR060471A1 true AR060471A1 (es) 2008-06-18

Family

ID=38625523

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070101608A AR060471A1 (es) 2006-04-17 2007-04-16 Organismos clostridium recombinantes atenuados y vacuna
ARP110100176A AR079941A2 (es) 2006-04-17 2011-01-19 Organismos clostridium atenuados recombinados y vacuna

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110100176A AR079941A2 (es) 2006-04-17 2011-01-19 Organismos clostridium atenuados recombinados y vacuna

Country Status (23)

Country Link
US (3) US7732187B2 (es)
EP (2) EP2007420B1 (es)
JP (2) JP5551933B2 (es)
KR (1) KR20080110908A (es)
CN (1) CN101489584B (es)
AR (2) AR060471A1 (es)
AU (1) AU2007240949B2 (es)
BR (1) BRPI0711572A2 (es)
CA (1) CA2649426C (es)
CO (1) CO6140037A2 (es)
EC (1) ECSP088827A (es)
ES (1) ES2401810T3 (es)
IL (1) IL194714A (es)
MX (1) MX2008013451A (es)
NO (1) NO20084810L (es)
NZ (1) NZ571970A (es)
PE (1) PE20080167A1 (es)
PL (1) PL2007420T3 (es)
RU (2) RU2445364C2 (es)
TW (1) TWI338045B (es)
UA (2) UA109105C2 (es)
WO (1) WO2007123850A2 (es)
ZA (1) ZA200808872B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US20060083750A1 (en) * 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
EP2283358B1 (en) * 2008-04-29 2015-04-22 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
CA2811056A1 (en) * 2010-09-10 2012-03-15 Viropharma Incorporated Environmental clostridial bacteriotherapy and related formulations and methods of manufacture and use
CN103998056B (zh) 2011-07-22 2017-09-12 诺瓦蒂格姆疗法有限公司 用于接种抗金黄色葡萄球菌疫苗的方法和组合物
HK1200463A1 (en) * 2012-03-02 2015-08-07 瑞泽恩制药公司 Human antibodies to clostridium difficile toxins
US9687540B2 (en) 2012-10-26 2017-06-27 Intervet Inc. Cross-protecting Salmonella vaccines
EP2968497B1 (en) 2013-03-15 2020-08-12 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Compositions and methods for treating fungal and bacterial pathogens
US10857216B2 (en) 2016-03-09 2020-12-08 Novadigm Therapeutics, Inc. Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN109602898B (zh) * 2018-12-28 2022-02-22 江苏省农业科学院 一种产气荚膜梭菌α毒素基因工程疫苗及其制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
GB202019767D0 (en) * 2020-12-15 2021-01-27 Chain Biotechnology Ltd Compostitions and methods
CN114621963A (zh) * 2022-03-11 2022-06-14 牧原食品股份有限公司 一种猪魏氏梭菌a型的亚单位疫苗及其制备
CN116970505A (zh) * 2022-04-22 2023-10-31 金宇保灵生物药品有限公司 一种A型产气荚膜梭菌α毒素的产毒培养基及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1483042A (en) 1974-07-29 1977-08-17 Lapointe J Anti-tumour product of bacterial origin
SU627610A1 (ru) 1977-09-30 1980-02-05 Zemlyakova V P Препарат землаково в.п. против клюстридиозов животных и птиц
GB9115332D0 (en) * 1991-07-16 1991-08-28 Connaught Lab Manipulation of gene copy number in bordetella
ATE226635T1 (de) * 1992-05-20 2002-11-15 Secr Defence Clostridium perfringens impfstoffe
GB9605222D0 (en) 1996-03-12 1996-05-15 Secr Defence Clostridium perfringens epsilon toxin vaccines
PT892054E (pt) 1997-06-20 2007-02-28 Intervet Int Bv Vacina de clostridium perfringens
RU2129441C1 (ru) * 1997-12-10 1999-04-27 Пирожков Михаил Константинович Вакцина, ассоциированная против анаэробной энтеротоксемии и эшерихиоза поросят
US6399074B1 (en) * 1998-07-24 2002-06-04 Megan Health, Inc. Live attenuated salmonella vaccines to control avian pathogens
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
AU2003297719A1 (en) * 2002-12-09 2004-06-30 University Of Georgia Research Foundation, Inc. Coccidial vaccine and methods of making and using same
CA2545325C (en) * 2003-11-10 2015-01-13 Uab Research Foundation Compositions for reducing bacterial carriage and cns invasion and methods of using same
MY149604A (en) 2005-04-18 2013-09-13 Schering Plough Ltd C.perfringens alpha toxoid vaccine

Also Published As

Publication number Publication date
CA2649426C (en) 2014-04-01
NZ571970A (en) 2012-02-24
CO6140037A2 (es) 2010-03-19
ECSP088827A (es) 2008-11-27
ES2401810T3 (es) 2013-04-24
EP2007420A2 (en) 2008-12-31
PL2007420T3 (pl) 2013-08-30
CN101489584B (zh) 2013-05-01
US20070286874A1 (en) 2007-12-13
BRPI0711572A2 (pt) 2011-11-16
RU2008144913A (ru) 2010-05-27
JP2013255518A (ja) 2013-12-26
WO2007123850A3 (en) 2008-03-06
US7807456B2 (en) 2010-10-05
WO2007123850A2 (en) 2007-11-01
UA95951C2 (en) 2011-09-26
CA2649426A1 (en) 2007-11-01
RU2593945C2 (ru) 2016-08-10
US7732187B2 (en) 2010-06-08
AU2007240949B2 (en) 2013-03-14
ZA200808872B (en) 2009-11-25
AU2007240949A1 (en) 2007-11-01
EP2007420B1 (en) 2013-03-06
TW200801182A (en) 2008-01-01
JP5551933B2 (ja) 2014-07-16
MX2008013451A (es) 2008-10-30
KR20080110908A (ko) 2008-12-19
UA109105C2 (uk) 2015-07-27
PE20080167A1 (es) 2008-03-10
RU2445364C2 (ru) 2012-03-20
US7972604B2 (en) 2011-07-05
JP2009533071A (ja) 2009-09-17
HK1125315A1 (en) 2009-08-07
CN101489584A (zh) 2009-07-22
EP2368571A1 (en) 2011-09-28
IL194714A0 (en) 2011-08-01
US20100166800A1 (en) 2010-07-01
AR079941A2 (es) 2012-02-29
US20110008389A1 (en) 2011-01-13
NO20084810L (no) 2009-01-16
TWI338045B (en) 2011-03-01
RU2011147308A (ru) 2013-05-27
IL194714A (en) 2015-03-31

Similar Documents

Publication Publication Date Title
AR060471A1 (es) Organismos clostridium recombinantes atenuados y vacuna
PE20161551A1 (es) Vacuna de pcsk9
DK1968632T3 (da) Forbedret influenzavaccine
AR074311A1 (es) Variantes de subtilisina aislada de bacillus, con actividad proteolitica
WO2008156778A3 (en) Influenza m2 protein mutant viruses as live influenza attenuated vaccines
AR061930A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, metodos y usos
AR040204A1 (es) Composicion de vacuna meningococica multivalente
WO2005021707A3 (en) Severe acute respiratory syndrome dna vaccine compositions and methods of use
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
AR124928A2 (es) Vacuna de herpesvirus-1 equino recombinante que contiene glicoproteína c mutada y usos de la misma
ATE547118T1 (de) Rekombinanter koi-herpesvirus (khv) oder cyprinid-herpesvirus 3 (cyhv-3) und impfstoff zur prävention einer von khv/cyhv-3 bei cyprinus carpio carpio oder cyprinus carpio koi verursachten erkrankung
ES2421447T3 (es) Métodos para proteger frente a apoptosis usando lipopéptidos
NZ592911A (en) Leukolectins and uses thereof
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
NZ602380A (en) Peptides for vaccine against birch allergy
NZ594268A (en) Grass peptides for vaccine
WO2006128100A3 (en) Chondrogenic compositions and methods of use
AR075933A1 (es) Composiciones polipeptidas y de inmunizacion conteniendo polipeptidos positivos gram y metodos de uso
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
ES2192559T3 (es) Vacuna para la proteccion de aves de corral contra la coccidiosis.
BR112014001844A2 (pt) gene induzindo o alongamento de raízes ou aumentando a biomassa, e uso do mesmo
PE20120116A1 (es) Composicion inmunogenica multicomponente para la prevencion de enfermedad estreptococica beta hemolitica (bhs)
NZ601616A (en) Method for producing interferon alpha 5

Legal Events

Date Code Title Description
FG Grant, registration